UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
01. Februar 2021 08:00 ET
|
Unity Biotechnology, Inc.
Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz,...
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
16. Dezember 2020 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors
14. Dezember 2020 07:00 ET
|
Unity Biotechnology, Inc.
Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board Changes Reflect Strategic Focus on Clinical Development in Age-Related Diseases of the Eye and Brain ...
UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates
04. November 2020 16:01 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
12. Oktober 2020 08:00 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
15. September 2020 08:00 ET
|
Unity Biotechnology, Inc.
- Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. ...
UNITY Biotechnology to Participate in Upcoming September Investor Conferences
04. September 2020 08:00 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces Appointment of Lynne Sullivan as Chief Financial Officer
31. August 2020 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee
17. August 2020 07:00 ET
|
Unity Biotechnology, Inc.
UBX0101 failed to meet 12-week primary endpointGuidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchangedUNITY to focus senescence programs on ophthalmologic and neurologic...
UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital
04. August 2020 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...